TY - CHAP
T1 - Collection, processing, and banking of umbilical cord blood
AU - Harris, David T.
N1 - Funding Information:
Dr. Ghofrani discloses grants from German Research Foundation during the work, and personal fees from Actelion, Bayer, GSK, Novartis, Pfizer, Bellerophon Pulse Technologies, and MSD Merck Sharpe & Dohme outside the submitted work. None of the other authors declare a conflict of interest.
Publisher Copyright:
© 2014 Springer Science+Business Media New York. All rights reserved.
PY - 2014/4/1
Y1 - 2014/4/1
N2 - The blood in the umbilical cord and placenta after the birth of a child is comparable to bone marrow for use in hematopoietic stem cell transplantation and offered a number of advantages. In the past 20 years, more than 30,000 cord blood transplants have been performed worldwide. Stem cell transplantation for hematological malignancies and genetic disorders however, is an uncommon occurrence. Research performed by several independent laboratories has demonstrated that cord blood also contains a mixture of pluripotent stem cells capable of giving rise to cells derived from the endodermal, mesodermal, and ectodermal lineages. Thus, CB is a readily available stem cell source for use in tissue engineering and regenerative medicine applications, which are hypothesized to be more frequent events than the need for hematopoietic stem cell transplant. This chapter will review the methodologies for collection, processing, and banking these cells for these future clinical uses.
AB - The blood in the umbilical cord and placenta after the birth of a child is comparable to bone marrow for use in hematopoietic stem cell transplantation and offered a number of advantages. In the past 20 years, more than 30,000 cord blood transplants have been performed worldwide. Stem cell transplantation for hematological malignancies and genetic disorders however, is an uncommon occurrence. Research performed by several independent laboratories has demonstrated that cord blood also contains a mixture of pluripotent stem cells capable of giving rise to cells derived from the endodermal, mesodermal, and ectodermal lineages. Thus, CB is a readily available stem cell source for use in tissue engineering and regenerative medicine applications, which are hypothesized to be more frequent events than the need for hematopoietic stem cell transplant. This chapter will review the methodologies for collection, processing, and banking these cells for these future clinical uses.
UR - http://www.scopus.com/inward/record.url?scp=84929714742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929714742&partnerID=8YFLogxK
U2 - 10.1007/978-1-4939-1118-9_24
DO - 10.1007/978-1-4939-1118-9_24
M3 - Chapter
AN - SCOPUS:84929714742
SN - 1493911171
SN - 9781493911172
SP - 261
EP - 267
BT - Perinatal Stem Cells
PB - Springer New York
ER -